Background: Autosomal recessive hypercholesterolemia (ARH) is an extremely rare inherited hypercholesterolemia, the cause of which is mutations in low-density lipoprotein (LDL) receptor adaptor protein 1 (LDLRAP1) gene.
Introduction
Familial hypercholesterolemia (FH) is an inherited disease characterized by the triad of (1) hypercholesterolemia due to a high level of plasma LDL, (2) tendon xanthomas and (3) premature coronary artery disease [1] . Patients with homozygous FH have been defined as who have two mutant alleles of either of three following FH-associated genes: LDLR, apolipoprotein B (ApoB) gene and proprotein convertase subtilisin/kexin type 9 (PCSK9) [2] . Previously, we identified several homozygous FH patients who possessed double heterozygous mutations in LDLR gene and PCSK9 gene in relatively mild phenotypic patients compared with those with double mutations in LDLR gene [3] . In addition to autosomal dominant types of FH, recessive form of FH-associated gene was identified in 1992 [4] . The null mutations in the LDL receptor adaptor protein 1 (LDLRAP1) gene, which serves as an adaptor for LDLR endocytosis in the liver, causes autosomal recessive hypercholesterolemia (ARH) [5] . It is described that several heterozygous LDLRAP1 mutation carrier showed elevated LDL-C levels [6, 7] . However, there is no data on clinical significance of adding a mutation in LDLRAP1 gene onto single LDLR gene mutation.
Methods

Study subjects
been described the existence of the rebound effect after transient suspension of statin therapy [8] , it is also reported that short-term suspension of statins is safe for at least patients with stable cardiovascular disease [9] . Complications related to this short-term suspension of lipid-lowering therapy have not been observed so far in our institute. The characteristics of the study subjects were listed in Table 1 and supplementary Table. 2
.2 Biochemical analysis
Serum concentrations of total cholesterol (TC), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C) were determined enzymatically. LDL-C concentrations were derived using the Friedewald formula. Apolipoprotein E (ApoE) phenotype was separated by isoelectric focusing and detected by Western blot with apoE polyclonal antibody (phenotyping apoE IEF system, JOKOH, Tokyo, Japan). Plasma cholesteryl ester transfer protein (CETP) levels were determined by a specific ELISA [10] .
Genetic analysis
Genomic DNA was isolated from peripheral blood white blood cells according to standard procedures and was used for PCR. Primers for the study were as used previously [3, 11] ; PCR products were purified by Microcon (Millipore Corp., Bedford, MA) and used as templates for direct sequencing. DNA sequencing was carried out according to the manufacturer's instructions using a dye terminator method (ABI PRISM TM 310 Genetic Analyzer (PerkinElmer Biosystems, Waltham, MA). We screened the study subjects for all coding region of PCSK9 and LDLRAP1
genes as candidate genes that could affect their lipid profile and clinical phenotype. In addition, we analyzed the two common mutations of the CETP gene (c.1321+1G>A, previously described as Int14A and c.1376A>G, previously described as D442G) among Japanese population as previously described [12] .
Results
Biochemical analysis
Serum lipids and apolipoproteins in the proband and her pedigree are presented in Table 2 .
Sequence of LDLR gene
Mutation in LDLR gene of the proband (c.2431A>T) was one of the most common mutations in Japan [13] (Supplementary Figure 1A) .
Sequence analysis of candidate genes for inherited hypercholesterolemia
Although there was no genetic abnormality in her PCSK9 gene, we identified another heterozygous mutation in her LDLRAP1 gene (c.606dup, Supplementary Figure 1B) .
Clinical course of the proband
At the age of 67, she was diagnosed as FH due to severe hypercholesterolemia with Achilles' tendon thickness (Supplementary Figure 2) . Initial levels of TC, TG, and HDL-C concentrations were 367, 108, and 46 mg/dl, respectively under statin therapy (pravastatin 20mg daily). She underwent coronary artery bypass graft surgery at the age of 70 due to angina pectoris. The more intensive cholesterol lowering therapy using atorvastatin 20mg daily was introduced for secondary prevention of cardiovascular disease. She was referred to our hospital for further examination of her hypercholesterolemia and coronary artery disease at the age of 78. Although her coronary atherosclerosis including bypass grafts did not progress substantially during 8 years ( Supplementary   Figure 3) , severe aortic valve stenosis developed causing her chest pain (Supplementary Figure 4) .
Although aortic valve replacement surgery was recommended, she refused due to potential complications derived from extreme high age.
Family study
Family study was performed as intensively as possible to find another family member with LDLR or LDLRAP1 mutation. We identified two other relatives with double mutations, and one obligate carrier who died suddenly probably due to cardiac event in his forties (Figure 2 ).
Genetic analysis for CETP gene
There was no carrier for both of common CETP gene mutation in this family.
Discussion
Patients with homozygous FH have two mutant alleles of either of three FH-associated genes (FH genes), namely LDLR, apolipoprotein B-100 and PCSK9 genes. In addition to those dominant form inherited gene mutation recessive form of null mutations in LDLRAP1 gene also causes FH (autosomal recessive hypercholesterolemia:ARH). There are few published data about the clinical characteristics of LDLRAP1 heterozygous mutation carriers because of rarity of this disorder.
Previously, we have shown that c.606dup mutation carriers in LDLRAP1 gene had elevated LDL-C concentrations compared with non-carrier family members [14] , suggesting that "autosomal recessive hypercholesterolemia " is not necessarily a correct term.
In this paper, we report the first family which exhibit double mutations in LDLR and LDLRAP1 gene with severe xanthomas and coronary artery disease as well as the episode of ventricular fibrillation due to aortic valve stenosis. Besides the proband, we found two other relatives in her family with the same double mutations in LDLR and LDLRAP1 gene.
Some of the pedigrees, including double mutation carriers exhibit relatively high HDL-C level.
Previously, we reported that the CETP gene mutations causing higher HDL-C levels are common in Japan [12] . However, there was no carrier of two common CETP gene mutations (c.1321+1G>A
and c.1376A>G) among this family member. The plasma levels of CETP of this family member were within normal limit, suggesting absence of CETP deficiency. It has been reported that the causes of high HDL-C level were quite heterogeneous [15] . Thus, we cannot exclude the possibility that unknown genetic factors may be involved in their high HDL-C levels. Another possibility of higher HDL-C is their excessive alcohol drinking. The pedigrees whose HDL-C levels were more than 90 mg/dl (II-1 and II-2) were both heavy drinkers (ethanol > 120g/day).
In conclusion, we report the first family with double mutation in LDLR and LDLRAP1 genes associated with autosomal dominant and recessive form of hypercholesterolemia. Although the proband exhibited massive Achilles tendon xanthoma and severe coronary and aortic valvular disease, serum LDL-C level of subjects with double mutations was similar with that of subjects with single LDLR mutation. We suggest that an additional mutation in LDLRAP1 may account for severer phenotype in terms of xanthoma and atherosclerotic cardiovascular disease in FH patients.
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